Alleviating Effect of Lafutidine on Toxicity of S-1: Adjuvant Chemotherapy of Gastric Cancer (AEOLUS).

Trial Profile

Alleviating Effect of Lafutidine on Toxicity of S-1: Adjuvant Chemotherapy of Gastric Cancer (AEOLUS).

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 20 Jan 2018

At a glance

  • Drugs Lafutidine (Primary) ; Gimeracil/oteracil/tegafur
  • Indications Gastric cancer
  • Focus Therapeutic Use
  • Acronyms AEOLUS
  • Most Recent Events

    • 20 Jan 2018 Primary endpoint has not been met. (Treatment completion rate), as reported in an abstract presented at the 2018 Gastrointestinal Cancers Symposium.
    • 20 Jan 2018 Results presented at the 2018 Gastrointestinal Cancers Symposium
    • 07 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by University Hospital Medical Information Network - Japan.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top